phrykt

Vivos Therapeutics, Inc. (VVOS): who owns it and who trades it

As of Nov 16, 2026, VVOS insiders reported 2 purchases worth $1.8M in the last 12 months. The largest buyer was V-Co Investors 3 LLC (10% owner), with $1.8M. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vivos Therapeutics

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, VVOS insiders reported $1.8M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.8M
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Mar 31, 2026
Filed Apr 2, 2026

Purchases and sales by month

$1.8M$1.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 31, 2026V-Co Investors 3 LLC +110% ownerPurchase308,848$1.34$414KForm 4
Mar 31, 2026V-Co Investors 3 LLC +110% ownerPurchase1.04M$1.34$1.4MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
V-Co Investors 3 LLC10% owner$1.8M–Mar 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VVOS short interest

Very high short interest. 22.1% of VVOS shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 214%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.07M VVOS shares were sold short, 22.1% of the shares outstanding, up 30.1% from the report before. At the average daily volume of 12.31M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

22.1%May 15Oct 3024.5%

Days to cover

1.0May 15Oct 308.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.07M22.08%+30%12.31M1.0
Oct 15, 20262.36M16.97%-18%2.43M1.0
Sep 30, 20262.86M20.61%+76%8.03M1.0
Sep 15, 20261.63M11.70%-35%9.03M1.0
Aug 31, 20262.50M18.02%+100%49.53M1.0
Aug 14, 20261.25M8.99%+4%5.55M1.0
Jul 31, 20261.20M8.65%-0%154,1847.8
Jul 15, 20261.20M8.66%+3%195,3156.2
Jun 30, 20261.17M8.45%+24%1.69M1.0
Jun 15, 2026947,4416.82%+20%7.02M1.0
May 29, 2026786,5985.66%-20%160,2384.9
May 15, 2026978,0657.25%+37%151,8026.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vivos Therapeutics company events

Vivos Therapeutics filed 23 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing, auditor). The latest was on Oct 21, 2026.

  1. Oct 21, 2026AnnouncementAs previously disclosed, in April 2026 Vivos Therapeutics, Inc. received a deficiency notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC stating that the Company did not comply with the continued listing requirements of Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or… Filing
  2. Oct 19, 2026DealOn the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD, representing at least eleven percent (11%) of SOD’s fully diluted capital stock immediately after the Closing (as adjusted, in accordance with Section 1.1 of the Agreement, from the 2,907,338… Filing
  3. Oct 15, 2026AgreementVivos Therapeutics, Inc., a Delaware corporation, entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences, Inc., a Florida corporation. Filing
  4. Oct 1, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  5. Sep 8, 2026AgreementAmended an earlier report. As previously reported, the Company previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company, a Secured Promissory Note with an original issuance date of June 9, 2025 in the original principal amount of $8.22 million (as amended by that certain Amendment to Secured… Filing
  6. Sep 8, 2026AgreementAs previously reported, Vivos Therapeutics, Inc. previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company, a Secured Promissory Note with an original issuance date of June 9, 2025 in the original principal amount of $8.22 million (as amended by that certain… Filing
  7. Aug 21, 2026AnnouncementShared information with investors. Filing
  8. Aug 11, 2026AnnouncementShared information with investors. Filing
  9. Aug 3, 2026LeadershipOf this Current Report on Form 8-K regarding the Separation, Resignation and Executive Transition Agreement, dated as of July 31, 2026, between Vivos Therapeutics, Inc. and Bradford Amman, and the Master Services Agreement, dated as of July 31, 2026, between the Company and The CFO Portal, LLC, is… Filing
  10. Jul 7, 2026AgreementVivos Therapeutics, Inc., a Delaware corporation entered into a Securities Purchase Agreement with V-Co Investors 4 LLC, a Wyoming limited liability company and Bigger Capital Fund, LP. Filing
  11. Jun 25, 2026AgreementAs previously announced, Vivos Therapeutics, Inc. entered into an Exchange Agreement with Streeterville Capital, LLC, a Utah limited liability company, on June 5, 2026. Filing
  12. Jun 16, 2026AnnouncementVivos Therapeutics, Inc. issued a press release announcing its intention to file a registration statement with the U.S. Securities and Exchange Commission for a proposed rights offering, pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its… Filing
  13. Jun 16, 2026AgreementVivos Therapeutics, Inc. entered into a Collaboration Agreement with South Palm Cardiovascular Associates, LLC, a Florida limited liability company, pursuant to which the parties agreed to collaborate in the formation and operation of a new management services organization to be known as AIM… Filing
  14. Jun 8, 2026ListingThe Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to… Filing
  15. Apr 22, 2026ListingVivos Therapeutics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025, did not satisfy the continued listing requirement… Filing
  16. Apr 15, 2026ResultsReleased financial results. Filing
  17. Apr 3, 2026AgreementVivos Therapeutics, Inc., a Delaware corporation entered into a Securities Purchase Agreement with V-Co Investors 3 LLC, a Wyoming limited liability company. Filing
  18. Feb 6, 2026LeadershipThe Board of Directors of Vivos Therapeutics, Inc., pursuant to the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Gregg C. E. Johnson as an independent director of the Board. Filing
  19. Jan 20, 2026AgreementAs previously reported, Vivos Therapeutics, Inc., a Delaware corporation, entered into the following private placement transactions with an institutional investor pursuant to which the Company issued to the Holder (i) a Common Stock Purchase Warrant, issued on January 9, 2023, to purchase up to… Filing
  20. Jan 16, 2026AgreementVivos Therapeutics, Inc. entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC in the maximum principal amount of up to $5.5 million (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal… Filing
  21. Dec 17, 2025AnnouncementMade another announcement. Filing
  22. Dec 5, 2025AgreementVivos Therapeutics, Inc., a Delaware corporation, entered into a Note Purchase Agreement with from Avondale Capital, LLC, a Utah limited liability company, pursuant to which the Company issued and sold to Lender a Promissory Note in the original principal amount of $2.09 million (the “ Principal… Filing
  23. Nov 19, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vivos Therapeutics financials

Famous investors that hold VVOS

1 of the 50 well-known investors we track reported holding VVOS in their latest 13F filing. The largest position is Ken Griffin's, worth $72.7K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026491,378$72.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Vivos Therapeutics, Inc. (VVOS) stock

Are VVOS insiders buying or selling?

In the last 12 months, VVOS insiders reported 2 open-market purchases worth $1.8M and no sales. The latest trade was on Mar 31, 2026. See every trade.

What is the short interest in VVOS?

As of Oct 30, 2026, 3.07M VVOS shares were sold short, 22.1% of the shares outstanding, up 30.1% from the report before. At the average daily volume of 12.31M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold VVOS?

1 of the 50 well-known investors we track reported VVOS in their latest 13F filing, including Ken Griffin. The largest position is worth $72.7K. See all holders.

Executive pay

Vivos Therapeutics's chief executive was paid a total of $511K for the year ended Dec 31, 2025, down 61% from $1.3M the year before. In the last 12 months, Vivos Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$511KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$358KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.